Serotonin Syndrome Versus NMS in a Patient on an MAOI
A 44-year-old woman with treatment-resistant depression is on tranylcypromine 40 mg/day. She develops a severe migraine and is given sumatriptan by urgent care. Within 6 hours she becomes agitated, diaphoretic, and confused. Exam: T 38.9 C, HR 126, BP 172/98, diffuse hyperreflexia with clonus in the lower extremities, dilated pupils, and hyperactive bowel sounds. She is tremulous but has no rigidity. CK is 380 U/L (mildly elevated). She took an over-the-counter cold preparation containing dextromethorphan the night before.
1. Distinguish serotonin syndrome from neuroleptic malignant syndrome in this case.
Read the worked answer
This presentation is most consistent with serotonin syndrome (SS), a toxicity from serotonergic excess. Key distinguishing features:
| Feature | Serotonin syndrome | NMS |
|---|---|---|
| Onset | Rapid (hours) | Gradual (days) |
| Neuromuscular | Hyperreflexia, clonus (especially lower extremities) | Lead-pipe rigidity, bradyreflexia |
| Pupils | Mydriasis | Normal or mydriasis (less prominent) |
| Bowel sounds | Hyperactive | Normal or decreased |
| Temperature | Often < 41 C | Often > 41 C |
| CK | Mildly elevated | Markedly elevated |
| Cause | Serotonergic drugs | Dopamine antagonists/withdrawal |
The MAOI + sumatriptan + dextromethorphan combination is a classic serotonergic trigger. Clonus and hyperreflexia are the most specific findings. The absence of rigidity and only mild CK elevation argue against NMS. However, both can coexist if antipsychotics are also involved, and severe SS can progress to rigidity and rhabdomyolysis.
2. What is the immediate management, and which medications must be stopped?
Read the worked answer
Immediate management:
- Discontinue all serotonergic agents: tranylcypromine, sumatriptan, dextromethorphan-containing products. Do not give additional serotonergic agents (e.g., tramadol, linezolid, methylene blue).
- Supportive care: IV fluids, cooling for hyperthermia, benzodiazepines (e.g., lorazepam) for agitation and to reduce hyperthermia, continuous monitoring.
- Cyproheptadine (5-HT2A antagonist) may be considered for moderate–severe cases (e.g., 12 mg initially, then 2 mg q2h as needed), though evidence is limited.
- Avoid antipyretics alone (acetaminophen does not treat the central mechanism) and avoid physical restraints (worsen hyperthermia and rigidity).
- Intubation/paralysis with non-depolarizing agents if severe hyperthermia or rigidity develops; avoid succinylcholine if hyperkalemia risk.
- Monitor CK, renal function, electrolytes, ECG (QTc).
Critical drug interaction warning: MAOIs have many interactions (sympathomimetics, meperidine, tramadol, linezolid, dextromethorphan, SSRIs, triptans). The patient needs a medication alert and education.
3. How do you counsel her about future migraine and cold treatment, and what is the longer-term plan?
Read the worked answer
Counsel that triptans and dextromethorphan are contraindicated with an MAOI and that she must check with the prescriber before any OTC product. Provide a written list of contraindicated medications and encourage pharmacy alerts.
For migraine: non-serotonergic options include acetaminophen, NSAIDs (if not otherwise contraindicated), antiemetics (avoid metoclopramide if concerns), and preventive agents such as topiramate, amitriptyline (caution), or propranolol - chosen with the psychiatrist. CGRP monoclonal antibodies are generally not serotonergic but require review.
For cold symptoms: saline, acetaminophen, and non-sedating antihistamines (avoid dextromethorphan and sympathomimetics).
Longer-term: reassess the risk–benefit of the MAOI given the interaction burden; if continued, ensure close monitoring, a crisis plan, and family education. Document the event and the counseling.